Literature DB >> 29600892

The Long and the Short of It in Cystic Fibrosis Clinical Research Outcomes.

Natalie E West1, Christopher H Goss2,3,4, David P Nichols3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29600892      PMCID： PMC5879146          DOI： 10.1513/AnnalsATS.201801-056ED

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  13 in total

1.  Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis.

Authors:  Michael W Konstan; Donald R VanDevanter; Gregory S Sawicki; David J Pasta; Aimee J Foreman; Evgueni A Neiman; Wayne J Morgan
Journal:  Ann Am Thorac Soc       Date:  2018-04

2.  Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.

Authors:  Gregory S Sawicki; James E Signorovitch; Jie Zhang; Dominick Latremouille-Viau; Markus von Wartburg; Eric Q Wu; Lizheng Shi
Journal:  Pediatr Pulmonol       Date:  2011-08-03

3.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

4.  A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.

Authors:  Mark R Elkins; Michael Robinson; Barbara R Rose; Colin Harbour; Carmel P Moriarty; Guy B Marks; Elena G Belousova; Wei Xuan; Peter T P Bye
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

5.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

6.  Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis.

Authors:  Michael W Konstan; Mark D Schluchter; Wei Xue; Pamela B Davis
Journal:  Am J Respir Crit Care Med       Date:  2007-09-13       Impact factor: 21.405

7.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Authors:  B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

8.  Effect of high-dose ibuprofen in patients with cystic fibrosis.

Authors:  M W Konstan; P J Byard; C L Hoppel; P B Davis
Journal:  N Engl J Med       Date:  1995-03-30       Impact factor: 91.245

9.  Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Karen S McCoy; Alexandra L Quittner; Christopher M Oermann; Ronald L Gibson; George Z Retsch-Bogart; A Bruce Montgomery
Journal:  Am J Respir Crit Care Med       Date:  2008-07-24       Impact factor: 21.405

10.  Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation.

Authors:  Kenneth J Rothman; Charles E Wentworth
Journal:  Epidemiology       Date:  2003-01       Impact factor: 4.822
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.